Trial register facet
Reported trial records — page 2
644 records with the status reported.
Showing 0 records on this page
Records
644 documents · page 2 of 27
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| SOUL-RENAL-IMPprogramme record | Semaglutide, oral | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| ESSENCE-PKprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| STRIDE-QOLprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| GLORY-1-QOLprogramme record | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ECNO-PH3-CN-OBESITY-REGIONAL-JPprogramme record | Ecnoglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ECNO-PH3-CN-T2D-ELDERLYprogramme record | Ecnoglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| EXENATIDE-GE-PD-DDIprogramme record | Exenatide | Phase 1 | Reported | Randomised crossover | — | 2025 | Very low |
| SURMOUNT-KOA-BODY-COMPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| SURPASS-CVOT-RENAL-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| ATTAIN-2-OLEprogramme record | Orforglipron | Phase 3 | Reported | Single-arm open-label | — | 2025 | Very low |
| ACHIEVE-1-BODY-COMPprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ACHIEVE-2-OLEprogramme record | Orforglipron | Phase 3 | Reported | Single-arm open-label | — | 2025 | Very low |
| REDEFINE-2-ELDERLYprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| SOUL-PKprogramme record | Semaglutide, oral | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| ESSENCE-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| STRIDE-REGIONAL-CNprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| GLORY-1-REGIONAL-CNprogramme record | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ECNO-PH3-CN-OBESITY-BODY-COMPprogramme record | Ecnoglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ECNO-PH3-CN-T2D-OLEprogramme record | Ecnoglutide | Phase 3 | Reported | Single-arm open-label | — | 2025 | Very low |
| EXENATIDE-GE-PD-HEPATIC-IMPprogramme record | Exenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| SURMOUNT-5-RENAL-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| ACHIEVE-1-QOLprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ACHIEVE-2-ADHERENCEprogramme record | Orforglipron | Phase 3 | Reported | Observational | — | 2025 | Very low |
| REDEFINE-1-ELDERLYprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
page 2 of 27